International Conference on Cardiology and Cardiovascular Medicine
Tuesday, 23 June 2026
๐ Celebrate Excellence in Cardiology & Cardiovascular Medicine!Nominations are now open for the Women Researcher Award at the 36th Edition of Cardiology Summit, taking place on 28–29 June 2026 in Bangkok, Thailand ๐น๐ญ. Recognizing outstanding women researchers with remarkable contributions and publications in cardiovascular science.
๐ Website: cardiology.pencis.com
๐บ YouTube Channel: Pencis Cardiology Awards
๐ Nomination Link: https://c-i.li/WUcJv
#cardiologyawards #womenresearcheraward #cardiology #cardiovascularmedicine #medicalresearch #healthcareinnovation #researchawards #bangkok2026 #womeninscience #cardiologysummit #pencis #globalresearch #medicalconference #hearthealth #scientificexcellence
Friday, 19 June 2026
Congratulations to Dr. Meryem Beyazal of Ankara Bilkent City Hospital, Turkey, on being nominated for the Research Excellence Award at the International Research Awards on Cardiology & Cardiovascular Medicine!
๐ Recognized for her valuable contributions to Pediatric Pulmonary Hypertension research, Dr. Beyazal continues to advance knowledge and improve outcomes for children affected by complex cardiovascular conditions.
๐ With 6 scientific publications, 7 citations, and an h-index of 2, this nomination celebrates her dedication to innovation, excellence, and impactful medical research.
๐ Honoring a researcher whose work is helping shape the future of pediatric cardiovascular care and inspiring the next generation of scientific discoveries.
✨ Excellence in research. Commitment to care. Impact that matters.
connect with us " click here "
#Congratulations #ResearchExcellenceAward #CardiologyAwards #CardiovascularMedicine #PediatricPulmonaryHypertension #MedicalResearch #HealthcareInnovation #InternationalResearchAwards #TurkeyResearch #ScientificExcellence #WomenInScience #ResearchImpact #AwardNominee
Tuesday, 16 June 2026
Congratulations to Prof. Zhengquan Gao of Binzhou Medical University, China, on being nominated for the Best Research Article Award at the International Research Awards on Cardiology & Cardiovascular Medicine!
๐ With remarkable contributions in the field of Marine Drugs research, Prof. Gao has demonstrated outstanding scientific excellence, reflected by an impressive 2,276 citations, 86 published documents, and an h-index of 28.
๐ This nomination recognizes a distinguished commitment to advancing research, fostering innovation, and creating a lasting impact on global healthcare and biomedical science.
✨ Celebrating research that inspires progress, transforms knowledge into action, and shapes the future of medicine.
#Congratulations #ResearchExcellence #BestResearchArticleAward #InternationalResearchAwards #CardiologyAwards #CardiovascularMedicine #MarineDrugs #ScientificInnovation #ResearchImpact #AcademicAchievement #BinzhouMedicalUniversity #ChinaResearch #GlobalResearch #HealthcareInnovation #MedicalResearch #AwardNominee #ResearchLeadership #FutureOfMedicine
Saturday, 13 June 2026
Congratulations to Mr. Jubran Al Hooti from University College Dublin, Ireland, on being nominated for the Research Excellence Award at the International Research Awards on Cardiology & Cardiovascular Medicine.
His outstanding research, "A Paradigm Shift in Myocardial Repair," represents a significant contribution to advancing cardiovascular science and innovative therapeutic approaches. We celebrate his dedication to research excellence and impactful scientific achievements.
#researchcellenceaward #cardiologyawards #cardiovascularmedicine #myocardialrepair #medicalresearch #cardiologyresearch #researchinnovation #scientificexcellence #healthcareinnovation #awardnominee #universitycollegedublin #irelandresearch #cardiologyscience #researchachievement #globalresearch #medicalinnovation #hearthealth #cardiovascularresearch #academicexcellence #internationalresearchawards
Monday, 8 June 2026
Atherosclerosis: A Major Cardiovascular Disease
Atherosclerosis is a chronic and progressive disease characterized by the accumulation of fatty deposits, cholesterol, inflammatory cells, and fibrous tissue within the walls of arteries. These deposits, commonly known as plaques, gradually narrow and harden the arteries, reducing blood flow to vital organs and tissues. As one of the leading causes of cardiovascular diseases worldwide, atherosclerosis is responsible for many life-threatening conditions, including coronary artery disease, heart attack, stroke, and peripheral artery disease. Due to its silent progression and widespread prevalence, understanding its causes, mechanisms, risk factors, prevention, and treatment is of great importance.
Pathophysiology of Atherosclerosis
The development of atherosclerosis begins with damage to the inner lining of the artery, known as the endothelium. Factors such as high blood pressure, smoking, elevated cholesterol levels, diabetes, and chronic inflammation can injure the endothelial cells. This damage allows low-density lipoprotein (LDL) cholesterol to penetrate the arterial wall, where it undergoes oxidation.
Oxidized LDL attracts immune cells, particularly macrophages, which engulf the cholesterol and transform into foam cells. The accumulation of foam cells forms fatty streaks, the earliest visible lesions of atherosclerosis. Over time, smooth muscle cells migrate into the affected area and produce fibrous tissue, creating a plaque with a lipid-rich core and a fibrous cap. As plaques enlarge, they narrow the arterial lumen and reduce blood flow. In some cases, plaques rupture, triggering the formation of blood clots that can completely block the artery, resulting in heart attacks or strokes.
Risk Factors
Atherosclerosis develops due to a combination of modifiable and non-modifiable risk factors.
Non-Modifiable Risk Factors
- Age: The risk increases with advancing age as arterial walls naturally lose elasticity.
- Gender: Men are generally at higher risk earlier in life, while women's risk rises significantly after menopause.
- Family History: A genetic predisposition to cardiovascular diseases can increase susceptibility.
Modifiable Risk Factors
- High LDL Cholesterol and Low HDL Cholesterol: Elevated LDL promotes plaque formation, while HDL helps remove cholesterol from arteries.
- Hypertension: High blood pressure damages the arterial lining, facilitating plaque development.
- Smoking: Tobacco toxins cause endothelial dysfunction and promote inflammation.
- Diabetes Mellitus: High blood glucose levels accelerate vascular damage and plaque progression.
- Obesity and Sedentary Lifestyle: Lack of physical activity and excess body weight contribute to metabolic abnormalities.
- Unhealthy Diet: Diets rich in saturated fats, trans fats, refined sugars, and processed foods increase cardiovascular risk.
- Chronic Stress: Persistent stress may contribute to hypertension and unhealthy lifestyle behaviors.
Clinical Manifestations
Atherosclerosis often remains asymptomatic for many years because plaques develop gradually. Symptoms usually appear only when blood flow becomes significantly restricted or when a plaque ruptures.
The clinical presentation depends on the affected arteries:
- Coronary Arteries: Chest pain (angina), shortness of breath, and myocardial infarction.
- Carotid Arteries: Transient ischemic attacks and ischemic stroke.
- Peripheral Arteries: Leg pain during walking (intermittent claudication), numbness, and poor wound healing.
- Renal Arteries: High blood pressure and impaired kidney function.
The silent nature of the disease underscores the importance of early detection and preventive measures.
Diagnosis
Several diagnostic methods help identify and assess atherosclerosis. Physicians often begin with a thorough medical history and physical examination, focusing on cardiovascular risk factors.
Common diagnostic tools include:
- Blood Tests: Measure cholesterol levels, blood glucose, and inflammatory markers.
- Electrocardiogram (ECG): Detects signs of reduced blood supply to the heart.
- Echocardiography: Evaluates cardiac structure and function.
- Ultrasound: Used to assess carotid artery plaques and blood flow.
- Computed Tomography (CT) Coronary Calcium Scoring: Estimates the extent of arterial calcification.
- Coronary Angiography: Provides detailed images of coronary artery blockages and remains the gold standard for diagnosis.
Prevention
Since many risk factors are modifiable, atherosclerosis is largely preventable through healthy lifestyle choices. Preventive strategies focus on reducing cardiovascular risk and slowing plaque progression.
A heart-healthy diet rich in fruits, vegetables, whole grains, lean proteins, fish, and unsaturated fats can significantly reduce cholesterol levels. Limiting salt, sugar, and processed foods also helps maintain cardiovascular health.
Regular physical activity, such as at least 150 minutes of moderate aerobic exercise per week, improves blood pressure, cholesterol levels, and body weight. Smoking cessation is one of the most effective measures to reduce cardiovascular risk. Maintaining a healthy body weight and effectively managing diabetes and hypertension are equally important preventive strategies.
Routine health check-ups and screening for cholesterol and blood pressure abnormalities enable early intervention before serious complications occur.
Treatment and Management
The treatment of atherosclerosis aims to prevent disease progression, relieve symptoms, and reduce the risk of complications. Management often involves a combination of lifestyle modifications and pharmacological therapy.
Lifestyle Changes
- Smoking cessation.
- Healthy dietary habits.
- Regular exercise.
- Weight management.
- Stress reduction.
Medications
- Statins: Lower LDL cholesterol and stabilize plaques.
- Antiplatelet Agents: Aspirin and similar drugs reduce the risk of blood clot formation.
- Antihypertensive Drugs: Control blood pressure and minimize arterial damage.
- Glucose-Lowering Medications: Improve glycemic control in diabetic patients.
Interventional Procedures
In severe cases where blood flow is critically reduced, invasive treatments may be necessary. These include:
- Percutaneous Coronary Intervention (PCI): Balloon angioplasty and stent placement to open blocked arteries.
- Coronary Artery Bypass Grafting (CABG): Surgical creation of alternative pathways for blood flow around obstructed arteries.
Recent Advances in Research
Recent research has expanded the understanding of atherosclerosis as an inflammatory disease rather than merely a disorder of cholesterol accumulation. Novel therapies targeting inflammatory pathways, such as interleukin-1 inhibitors, have demonstrated potential in reducing cardiovascular events. Advances in imaging technologies and the development of personalized medicine approaches are also improving risk assessment and treatment outcomes. Furthermore, studies investigating the role of genetics, gut microbiota, and artificial intelligence in cardiovascular risk prediction continue to shape the future of atherosclerosis management.
Conclusion
Atherosclerosis remains one of the most significant contributors to global morbidity and mortality. Its gradual and often silent progression makes early detection and prevention essential. By addressing modifiable risk factors through healthy lifestyle choices and appropriate medical management, the burden of this disease can be substantially reduced. Ongoing research continues to provide new insights into its complex mechanisms and offers hope for more effective therapies in the future. Ultimately, a combination of public health initiatives, patient education, and advances in medical science will play a crucial role in combating atherosclerosis and improving cardiovascular health worldwide.
For Enquiries: supportteam@pencis.
Thursday, 9 April 2026
Rising Cardiovascular Risks in Women: A Looming Public Health Challenge
Cardiovascular disease (CVD) has long been recognized as one of the leading causes of death worldwide, but emerging projections indicate that its impact on women in the United States is set to intensify dramatically over the coming decades. According to a recent scientific statement from the American Heart Association, the burden of heart disease and stroke among women is expected to rise sharply by 2050. This alarming trend is largely driven by increasing rates of high blood pressure, diabetes, and obesity—three major risk factors that continue to escalate across all age groups. The findings serve as a critical wake-up call for healthcare systems, policymakers, and individuals alike.
One of the most concerning aspects of the projection is the anticipated prevalence of hypertension among women. By 2050, nearly 60% of women in the U.S. are expected to have high blood pressure. Hypertension is often referred to as a “silent killer” because it can develop without noticeable symptoms while progressively damaging blood vessels and vital organs. Over time, uncontrolled high blood pressure significantly increases the risk of heart attacks, strokes, and kidney disease. The projected rise suggests that millions more women could be living with undiagnosed or poorly managed hypertension, further compounding the public health challenge.
In addition to hypertension, diabetes is another major contributor to the growing burden of cardiovascular disease. The prevalence of diabetes among women has been steadily increasing due to factors such as sedentary lifestyles, poor dietary habits, and rising obesity rates. Diabetes not only affects blood sugar regulation but also accelerates damage to blood vessels and the heart. Women with diabetes are at a particularly higher risk of developing cardiovascular complications compared to men, making this trend especially concerning. As the number of women living with diabetes increases, so too does the likelihood of cardiovascular events such as heart attacks and strokes.
Obesity plays a central role in this complex web of risk factors. Over the past few decades, obesity rates in the United States have surged, affecting individuals across all demographics. Excess body weight contributes to the development of both hypertension and diabetes, creating a vicious cycle that significantly elevates cardiovascular risk. Among younger women, this trend is particularly alarming. The projections indicate that by 2050, nearly one in three women aged 22 to 44 may already be living with some form of heart disease. This marks a shift from the traditional perception of cardiovascular disease as a condition primarily affecting older individuals.
The implications of these findings extend beyond individual health outcomes. A rising burden of cardiovascular disease among women will place immense pressure on healthcare systems, increasing the demand for medical services, long-term care, and specialized treatments. It will also have broader socioeconomic consequences, including reduced workforce participation, increased healthcare costs, and diminished quality of life for millions of women and their families. Addressing this issue will require a comprehensive and coordinated approach that spans prevention, early detection, and effective management.
Prevention remains the most powerful tool in combating the projected rise in cardiovascular disease. Lifestyle modifications such as maintaining a balanced diet, engaging in regular physical activity, and avoiding tobacco use can significantly reduce the risk of developing hypertension, diabetes, and obesity. Public health initiatives must focus on promoting these healthy behaviors, particularly among younger populations, to curb the progression of risk factors early in life. Education and awareness campaigns tailored specifically to women can also play a crucial role in encouraging proactive health management.
Early detection is equally important in mitigating the impact of cardiovascular disease. Regular health screenings for blood pressure, blood sugar levels, and cholesterol can help identify risk factors before they lead to more serious conditions. Healthcare providers must prioritize preventive care and ensure that women have access to affordable and timely medical services. Advances in digital health technologies, such as wearable devices and telemedicine, offer new opportunities for monitoring and managing health conditions more effectively.
Another critical aspect of addressing this challenge is the need for gender-specific research and treatment approaches. Historically, cardiovascular research has often focused on male populations, leading to gaps in understanding how the disease manifests and progresses in women. The current projections highlight the importance of investing in research that specifically addresses the unique biological and เคธाเคฎाเคिเค factors influencing women’s cardiovascular health. This includes studying hormonal influences, pregnancy-related complications, and differences in symptom presentation.
Policy interventions will also be essential in reversing the projected trends. Governments and health organizations must implement strategies to reduce the prevalence of risk factors at a population level. This may include regulations on unhealthy food products, initiatives to promote physical activity in communities, and programs to improve access to healthcare services. Collaboration between public and private sectors can further enhance the effectiveness of these efforts.
In conclusion, the projected rise in cardiovascular disease among women in the United States represents a significant public health challenge that demands immediate attention. With nearly 60% of women expected to develop high blood pressure and a substantial increase in diabetes and obesity rates, the risk of heart disease and stroke is set to escalate dramatically by 2050. However, this future is not inevitable. Through a combination of preventive measures, early detection, targeted research, and effective policy interventions, it is possible to alter the trajectory and improve health outcomes for millions of women. The time to act is now, before these projections become reality.
For Enquiries: supportteam@pencis.
Tuesday, 7 April 2026
Redefining Prevention: How Evolocumab Could Transform Early Heart Disease Management
Cardiovascular disease remains one of the leading causes of death worldwide, responsible for millions of fatalities each year. Traditionally, medical strategies to combat heart disease have focused on treating individuals after symptoms appear or after a cardiovascular event such as a heart attack or stroke has already occurred. However, a groundbreaking development involving the drug Evolocumab is challenging this reactive approach and paving the way for a new era of proactive prevention—particularly for high-risk individuals with diabetes.
Evolocumab belongs to a class of medications known as PCSK9 inhibitors, which have revolutionized cholesterol management in recent years. These drugs work by targeting a protein called PCSK9 that regulates the liver’s ability to remove low-density lipoprotein (LDL) cholesterol—often referred to as “bad cholesterol”—from the bloodstream. By inhibiting this protein, evolocumab allows the liver to clear more LDL cholesterol, resulting in dramatically lower levels in the blood.
Until recently, evolocumab has primarily been prescribed for patients who already have established cardiovascular disease or those who are unable to control cholesterol levels with traditional therapies such as statins. Its use has been largely confined to secondary prevention—preventing further complications in patients who have already experienced a cardiac event. However, emerging research suggests that its benefits may extend far beyond this traditional role.
In a significant new study, researchers explored the effects of evolocumab in high-risk individuals with diabetes who had not yet developed detectable atherosclerotic plaque—the fatty buildup in arteries that leads to heart attacks and strokes. The results were striking. Patients treated with evolocumab experienced a substantial reduction in the risk of first-time cardiovascular events, including heart attacks and strokes, even before any visible signs of artery damage were present.
This finding represents a major shift in how we understand and approach cardiovascular prevention. It suggests that the process leading to heart disease begins much earlier than previously thought and that intervening at a preclinical stage—before structural damage to arteries occurs—can yield significant protective benefits. For individuals with diabetes, who are already at an elevated risk for cardiovascular complications, this early intervention could be particularly life-changing.
Diabetes is known to accelerate the development of cardiovascular disease through multiple mechanisms, including chronic inflammation, endothelial dysfunction, and abnormal lipid metabolism. Even when cholesterol levels appear to be within a normal range, diabetic patients often have underlying metabolic disturbances that increase their susceptibility to heart disease. As a result, traditional risk assessment methods may underestimate their true risk.
By aggressively lowering LDL cholesterol at an earlier stage, evolocumab may help counteract these hidden risks. The drug’s ability to reduce LDL levels to extremely low concentrations—often far below what can be achieved with statins alone—provides an added layer of protection. This “ultra-low LDL” strategy is increasingly being recognized as a powerful tool in preventing cardiovascular events.
Another important implication of this research is the potential redefinition of treatment thresholds. Current guidelines typically recommend initiating intensive lipid-lowering therapy only after certain risk factors or clinical signs are present. However, the success of evolocumab in preventing first-time events suggests that earlier intervention in high-risk populations could yield better outcomes. This could lead to a paradigm shift in clinical practice, where prevention becomes more proactive rather than reactive.
Despite these promising findings, several important considerations remain. Evolocumab is a biologic drug administered via injection, and its cost has historically been a barrier to widespread use. Expanding its use to a broader population, including individuals without established cardiovascular disease, would require careful evaluation of cost-effectiveness and healthcare resource allocation. Policymakers and healthcare providers will need to balance the potential long-term benefits of preventing heart attacks and strokes against the immediate financial implications.
Safety is another critical factor. While evolocumab has been shown to be generally well-tolerated in clinical trials, long-term data on its use in primary prevention—especially in younger or asymptomatic individuals—are still needed. Ongoing studies will be essential to ensure that the benefits outweigh any potential risks over extended periods.
Moreover, it is important to emphasize that pharmacological interventions should complement, not replace, lifestyle modifications. A healthy diet, regular physical activity, smoking cessation, and effective management of blood sugar levels remain foundational elements of cardiovascular prevention. Evolocumab should be viewed as an additional tool in a comprehensive strategy to reduce risk, particularly for those who remain vulnerable despite optimal lifestyle and standard treatments.
The broader significance of this discovery lies in its potential to reshape the future of preventive medicine. By demonstrating that early, targeted intervention can prevent disease before it manifests, this research aligns with a growing emphasis on precision medicine—tailoring treatment to individual risk profiles and biological characteristics. It also highlights the importance of identifying high-risk populations, such as individuals with diabetes, who may benefit most from advanced therapies.
In conclusion, the emerging evidence surrounding evolocumab marks a pivotal moment in the fight against cardiovascular disease. By extending its use beyond secondary prevention and into the realm of early intervention, this powerful drug has the potential to reduce the incidence of first-time heart attacks and strokes in high-risk individuals. While further research and careful consideration are needed before widespread adoption, the implications are clear: the future of heart disease prevention may lie not in waiting for symptoms to appear, but in acting decisively before the disease takes hold.
For Enquiries: supportteam@pencis.
Get Connected here:
๐ Celebrate Excellence in Cardiology & Cardiovascular Medicine! Nominations are now open for the Women Researcher Award at the 36th E...
-
Aortic disease refers to conditions that affect the aorta, the largest artery in the body. The aorta carries oxygen-rich blood from the hea...
-
Artificial Intelligence (AI) is rapidly reshaping the landscape of modern medicine, and cardiology is one of the most promising areas witne...
-
A heart transplant is usually recommended for individuals with end-stage heart failure or severe heart conditions that do not respond to ot...


